Novartis Ag (NVSEF) Acquisitions (2009 - 2025)

Novartis Ag's (NVSEF) quarterly Acquisitions came in at -$21.0 million in Q4 2025, up 95.07% year-on-year from -$10.8 million in Q4 2024, and down 2200.0% quarter-over-quarter from $1.0 million in Q3 2025.

Novartis Ag (NVSEF) Acquisitions (2009 - 2025) Analysis & Trends

Novartis Ag has disclosed Acquisitions across 6 years of filings, most recently posting -$21.0 million for Q4 2025.

  • Acquisitions for Q4 2025 came in at -$21.0 million, up 95.07% year-over-year; the trailing twelve-month figure through Dec 2025 was -$504.0 million (down 4.13% YoY), and the FY2025 annual result was -$147.0 million, up 96.24% from the prior year.
  • Acquisitions came in at -$21.0 million for Q4 2025 at Novartis Ag, down from $1.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $1.0 million in Q3 2025 to a low of -$426.0 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -1.89 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 8.78 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 109.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 65.00 Mn
10 Novartis Ag - - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -21.00 Mn
Sep 30, 2025 1.00 Mn
Dec 31, 2024 -426.00 Mn
Sep 30, 2024 -58.00 Mn
Dec 31, 2015 -135.00
Sep 30, 2015 -228.00
Jun 30, 2015 -124.00
Dec 31, 2014 -350.00
Sep 30, 2014 -2.00
Jun 30, 2014 114.00
Mar 31, 2014 -93.00
Dec 31, 2013 -32.00
Sep 30, 2013 -10.00
Jun 30, 2013 -32.00
Dec 31, 2009 -35.00